Skip to main content
CVKD
NASDAQ Life Sciences

Cadrenal 10-Q: Going Concern Reiterated, Cash Runs to Q1 2027, Defective ATM Sales Ratified

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.4
Mkt Cap
$4.995M
52W Low
$0.816
52W High
$12.5
52W Position info
72% above low
Off High info
89% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CVKD sits 72% above its 52-week low of $0.816 on light trading volume (0.1× avg).

Summary

Cadrenal's Q3 10-Q reiterates substantial doubt about its ability to continue as a going concern, with $3.1 million of cash funding operations only into Q1 2027 and stockholders' equity just $0.4 million above Nasdaq's minimum. The filing also discloses board ratification of 83,834 ATM shares sold below the board-set price floor.


Key Events · Earnings and Guidance · CVKD

  • Going Concern Doubt Reiterated

    Management states substantial doubt exists about the company's ability to continue as a going concern for at least one year from issuance. With $3.1 million of cash at September 30, 2026 and $2.7 million in early November 2026, operations are funded only through the first quarter of 2027.

  • Nasdaq Equity Cushion Is Thin

    Stockholders' equity of $2.9 million at September 30, 2026 is only about $0.4 million above the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1). Market value of listed securities is below the $5 million threshold of a new rule that is currently stayed.

  • Defective ATM Sales Ratified

    On November 5, 2026 the board ratified under DGCL Section 204 the sale of 83,834 shares under the H.C. Wainwright ATM between June 8 and October 15, 2026 for gross proceeds of $156,724.93. The sales were made at prices below the board's $6.50 minimum and without the dual-officer sales notices the board required.

  • Strategic Review Is the Stated Path

    The October 7, 2026 review led by Tungsten Advisors is evaluating asset sales, out-licensing, partnerships, a business combination or reverse merger. The filing gives no timetable and warns the process may end without a transaction or in liquidation.


Analysis · CVKD · Life Sciences

Cadrenal ended September with $3.1 million in cash, an amount management says is not enough to fund the next twelve months. Runway reaches only into the first quarter of 2027, and the company will not start a trial it cannot fund. The only path it names is the strategic review with Tungsten Advisors announced October 7, which may end in asset sales, licensing, a merger or a reverse merger, or in liquidation. Against that backdrop the equity cushion is thin: $2.9 million of stockholders' equity sits just $0.4 million above Nasdaq's $2.5 million minimum, and market value of listed securities is under the $5 million threshold of a new listing rule that is currently stayed. The filing also discloses that the board had to ratify, under Delaware Section 204, 83,834 ATM shares sold between June and October for $156,724.93 at prices below the board's $6.50 floor and without the required dual-officer sales notices — a governance lapse on top of the cash problem. Losses are narrowing (Q3 net loss $1.25 million versus $2.69 million a year ago) mostly because spending was cut, not because the business is generating cash.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVKD was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.82 to $12.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVKD - Latest Insights

CVKD
Oct 07, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.20 info
Change: +$0.100 (+9%) info
Market Cap: $4.995M info
CVKD
Aug 31, 2026, 8:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.20 info
Change: -$0.300 (-20%) info
Market Cap: $4.995M info
CVKD
Aug 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $1.20 info
Change: -$0.430 (-26%) info
Market Cap: $4.995M info
CVKD
Aug 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.86
Real-time Price: $1.20 info
Change: -$0.660 (-35%) info
Market Cap: $4.995M info
CVKD
Aug 03, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.96
Real-time Price: $1.20 info
Change: -$0.760 (-39%) info
Market Cap: $4.995M info